# Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

> **NCT06313541** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 146 (estimated)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **RADIATION:** SBRT or LDRT
- **DRUG:** PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy

## Key facts

- **NCT ID:** NCT06313541
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313541, "Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06313541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*